Risks, harms and clinical implications of NPS – International Society for the Study of Emerging Drugs

Risks, harms and clinical implications of NPSMaster82022-04-27T21:51:51+00:00

Risks and harms of NPS from the user’s perspective and regional differences in prevalence: social research results from Germany

B. Werse (Germany)

Recreational stimulants compared to cannabis: a psychobiological overview

Parrott (UK)

New Psychoactive Substances: a threat to health security

Evans-Brown (EMCCDA)

Club drugs and induced psychopathology

Martinotti (Italy)

Acute effects of a moderate dose of a synthetic cannabinoid (JWC-018): implications for psychosis

E. L. Theunissen (The Netherlands)

Performance and Imaging Enhancing Drugs and related psychopathology: clinical issues

P. L. Simonato (Italy)

NPS, behaviour and the mind: controlled and naturalistic study with NPS

Ramaekers (The Netherlands)

Did the use of crystal meth increase with the ease of COVID 19 lockdown restrictions, leading to increased hospital admissions?

Manning et al (UK)

Clinical management of NPS in different settings (clinical cases)

Metastasio, O. Bowden-Jones (UK)